<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35053">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784120</url>
  </required_header>
  <id_info>
    <org_study_id>2011-GIRBA-2566</org_study_id>
    <nct_id>NCT01784120</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and toxicity of doxorubicin/Genexol-PM in metastatic breast cancer

        1. Primary Purpose: response rate

        2. Secondary purpose: toxicity, progression-free survival, overall survival
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>progression-free-survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>doxotubicin/Genexol-PM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin/Genexol-PM</intervention_name>
    <arm_group_label>doxotubicin/Genexol-PM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older adult women

          -  Instrumentation measurable lesions with histologically confirmed advanced (recurrent
             or metastatic) breast cancer

          -  ECOG 0-2

          -  Advanced breast cancer in the past, patients who did not receive chemotherapy

          -  Recurrence if adjuvant chemotherapy and adjuvant chemotherapy in the past for more
             than 6 months until the patient

          -  life expectancy more than 3 months

          -  Agree in writing before the party to participate in a clinical trial to patients

        Exclusion Criteria:

          -  immunohistochemical staining 3 + or FISH positive anti-HER 2 therapy patients

          -  Severe infections requiring antibiotic therapy

          -  Clinically significant heart disease

          -  Pregnant or lactating woman

          -  Uncontrolled symptoms in the central nervous system (CNS) metastases

          -  Patients diagnosed with malignant tumors of other organs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hee Kyung Ahn</last_name>
    <phone>+82-32-460-3229</phone>
    <email>hkahn@gilhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Kyung Ahn</last_name>
      <phone>+82-32-460-3229</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Eun Kyung Cho</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>genexol-PM</keyword>
  <keyword>paclitaxel</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
